Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 December 2006, Vol. 108, No. 13, pp. 3992-3996.
Prepublished online as a Blood First Edition Paper on August 17, 2006; DOI 10.1182/blood-2006-05-026112.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-05-026112v1
108/13/3992    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giuliani, N.
Right arrow Articles by Roodman, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giuliani, N.
Right arrow Articles by Roodman, G. D.
Related Collections
Right arrow Neoplasia
Right arrow Reviews in Translational Hematology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

REVIEW IN TRANSLATIONAL HEMATOLOGY

Multiple myeloma bone disease: pathophysiology of osteoblast inhibition

Nicola Giuliani, Vittorio Rizzoli, and G. David Roodman

From the Cattedra e Unità Operativa (UO) di Ematologia–Centro Trapianti Midollo Osseo (CTMO), Università Degli Studi di Parma, Italy; and University of Pittsburgh School of Medicine and Veterans Administration (VA) Medical Center, PA.

Abstract

Multiple myeloma (MM) is a plasma cell malignancy characterized by a high capacity to induce osteolytic bone lesions. Bone destruction in MM results from increased osteoclast formation and activity that occur in close proximity to myeloma cells. However, histomorphometric studies have demonstrated that MM patients with osteolytic bone lesions have lower numbers of osteoblasts and decreased bone formation. This impaired bone formation plays a critical role in the bone-destructive process. Recently, the biologic mechanisms involved in the osteoblast inhibition induced by MM cells have begun to be elucidated. In this article, the pathophysiology underlying osteoblast inhibition in MM is reviewed.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 RadioGraphicsHome page
C. J. Hanrahan, C. R. Christensen, and J. R. Crim
Current Concepts in the Evaluation of Multiple Myeloma with MR Imaging and FDG PET/CT
RadioGraphics, January 1, 2010; 30(1): 127 - 142.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Pennisi, W. Ling, X. Li, S. Khan, J. D. Shaughnessy Jr, B. Barlogie, and S. Yaccoby
The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
Blood, August 27, 2009; 114(9): 1803 - 1812.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, et al.
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
Ann. Onc., August 1, 2009; 20(8): 1303 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Hiruma, T. Honjo, D. F. Jelinek, J. J. Windle, J. Shin, G. D. Roodman, and N. Kurihara
Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation
Blood, May 14, 2009; 113(20): 4894 - 4902.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. Silvestris, S. Ciavarella, M. De Matteo, M. Tucci, and F. Dammacco
Bone-Resorbing Cells in Multiple Myeloma: Osteoclasts, Myeloma Cell Polykaryons, or Both?
Oncologist, March 1, 2009; 14(3): 264 - 275.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
A. Geffroy-Luseau, G. Jego, R. Bataille, L. Campion, and C. Pellat-Deceunynck
Osteoclasts support the survival of human plasma cells in vitro
Int. Immunol., June 1, 2008; 20(6): 775 - 782.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
G. D. Roodman
Skeletal Imaging and Management of Bone Disease
Hematology, January 1, 2008; 2008(1): 313 - 319.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Giuliani, F. Morandi, S. Tagliaferri, M. Lazzaretti, G. Donofrio, S. Bonomini, R. Sala, M. Mangoni, and V. Rizzoli
Production of Wnt Inhibitors by Myeloma Cells: Potential Effects on Canonical Wnt Pathway in the Bone Microenvironment
Cancer Res., August 15, 2007; 67(16): 7665 - 7674.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Terpos, O. Sezer, P. Croucher, and M.-A. Dimopoulos
Myeloma bone disease and proteasome inhibition therapies
Blood, August 15, 2007; 110(4): 1098 - 1104.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Giuliani, F. Morandi, S. Tagliaferri, M. Lazzaretti, S. Bonomini, M. Crugnola, C. Mancini, E. Martella, L. Ferrari, A. Tabilio, et al.
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients
Blood, July 1, 2007; 110(1): 334 - 338.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020